We come together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease.
On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies.
We continuously seek to understand the diverse perspectives of rare patients to courageously forge new paths that can make a difference in their lives and provide hope for today and tomorrow.
We are committed to broad access for our FDA-approved therapies, and we provide personalized clinical support services through the Total Care Hub.
We are dedicated to staying informed and engaged on topics that may impact the rare disease community, featuring community members and sharing what we learn. Find info at our Pathfinder.
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today provided a regulatory update for its sparsentan program in focal segmental glomerulosclerosis (FSGS).
One year ago – Mother’s Day 2020, I was two and a half months away from meeting my third and final baby girl. 2020 was a tough year for everyone with the COVID pandemic and living our new normal, but it was about to hit a peak for me when I got news just a month later I would have never fathomed. Read a message from Valarie, baby Delila’s mom
Thomas enjoys many things typical of twelve-year-old kids: sports, time with his friends, and playing video games. But Thomas’ journey has not always followed the typical path for kids his age.
SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2021 financial results and provided a corporate update.
Retrophin is now Travere Therapeutics.
© 2021 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.
Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
NewsSAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 PROTECT Study. The pivotal PROTECT Study is evaluating the safety and efficacy of sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder that often progresses to end-stage kidney disease (ESKD). Topline efficacy data from the interim 36-week proteinuria endpoint analysis are expected in August 2021.
Read the full press release >